Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04611230 · ClinicalTrials.gov registry record
A Study to Assess Infection Rate of Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2) and It's Affect on Quality of Life in Adult Volunteers in Lake County, Illinois
A clinical trial of Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2), sponsored by AbbVie.
- Completed
- Registry status
- 1,007
- Enrollment target
- 1
- Study location
NCT04611230: Completed study of Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2), sponsored by AbbVie.
NCT04611230 is a study of Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2) that has completed, run by AbbVie. The registered enrollment target is 1,007 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04611230, a study of Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2), has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- 1,007 participants
- Enrollment target
- 1
- Study location
Study Summary
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Lung failure is the main cause of death related to COVID-19 infection. The main objective of this study is to assess infection of SARS-CoV-2 and how quality of life is affected in adult volunteers in Lake County, Illinois. Volunteers will be recruited through digital advertisements and participants will be required to fill an online questionnaire. Upon consent, participants will be required to provide nasal swab and blood sample. Approximately 1250 adult volunteers living or working in Lake County, IL will be enrolled. Participants will be followed for approximately 9 months and will be required to provide nasal swab and blood samples every 3 months and complete questionnaires every 2 weeks. There may be higher treatment burden for participants in this trial. Participants will be monitored by medical assessments, blood tests and questionnaires.
Primary Outcome
SARS-CoV-2 infection prior to enrollment is assessed by Immunoglobulin G (IgG) serology testing and/or self-reported diagnosis.
Conditions Studied
Study Locations (1)
Illinois
- Great Lakes Clinical Trials /ID# 224874 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,007 participants |
| Start Date | 2020-11-05 |
| Est. Completion | 2021-10-27 |
What the finished NCT04611230 record still lists
NCT04611230 is an observational study that tracks outcomes without assigning an intervention. Its 1,007 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2) appearing as the primary indexed condition, and to 0 interventions.
NCT04611230 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT04611230 about?
NCT04611230 is a clinical study titled "A Study to Assess Infection Rate of Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2) and It's Affect on Quality of Life in Adult Volunteers in Lake County, Illinois". Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Lung failure is the main cause of death related to COVID-19 infection. The main objective of this study is to assess infection of SARS-CoV-2 and how quality of life is...
What is the current status of trial NCT04611230?
This trial is currently completed. The enrollment target is 1,007 participants. The study started on 2020-11-05. Estimated completion is 2021-10-27.
What conditions does trial NCT04611230 study?
This clinical trial studies the following conditions: Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2).
Who is sponsoring clinical trial NCT04611230?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04611230 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07191782 · 1,008 participants · NA
Examining the Efficacy of the PRAISE With Coaching Program
- NCT04389632 · 1,006 participants · Phase 1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- NCT06207864 · 1,001 participants · NA
Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI